Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemcitabine: safety profile unaffected by starting dose

C Martin1, C F Pollera

  • 1Lilly Research Centre, Windlesham, Surrey, UK.

International Journal of Clinical Pharmacology Research
|January 1, 1996
PubMed
Summary

Gemcitabine is a well-tolerated anticancer drug with a mild safety profile, showing minimal toxicity even at higher doses. This study confirms its broad therapeutic index for various solid tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome.

Journal of chemotherapy (Florence, Italy)·2006
Same author

A partial response in anaplastic carcinoma of the thyroid with liposomal doxorubicin.

Journal of experimental & clinical cancer research : CR·2005
Same author

Nephroblastoma in the adult.

Medical and pediatric oncology·1999
Same author

Does pain at tumor site during vinorelbine infusion affect treatment of recurrent head and neck cancer patients?

Annals of oncology : official journal of the European Society for Medical Oncology·1999
Same author

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.

European journal of cancer (Oxford, England : 1990)·1998

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Gemcitabine is an effective anticancer agent for solid tumors like lung and pancreatic cancer.
  • It exhibits a favorable safety profile compared to other oncolytics, with less severe side effects.
  • Classical toxicities such as alopecia, severe nausea, vomiting, and mucositis are infrequent.

Purpose of the Study:

  • To comprehensively evaluate the toxicity profile of gemcitabine.
  • To analyze safety data from a large patient cohort across multiple clinical studies.
  • To assess the impact of different starting doses on gemcitabine's toxicity.

Main Methods:

  • Integrated safety data from 790 patients across 18 completed clinical studies.
  • Gemcitabine administered as a 30-minute IV infusion weekly for three weeks, followed by a one-week rest period.
  • Subset analysis of 665 chemonaive patients based on starting doses (800, 1000, 1250 mg/m2).

Main Results:

  • Gemcitabine was confirmed to be well-tolerated with mild and short-lasting hematological toxicity.
  • Low incidence of infection, mild transaminase elevations, and rare clinically significant proteinuria/hematuria were observed.
  • No cumulative hepatic or renal toxicity, mild nausea/vomiting, and rare hair loss were noted.
  • Dose escalation showed minimal, clinically insignificant toxicity differences, with no increased infection rates despite higher neutrophil counts.

Conclusions:

  • Gemcitabine demonstrates a favorable safety profile and is well-tolerated in cancer patients.
  • The drug possesses a broad therapeutic index, suggesting potential for higher dose utilization.
  • Clinical studies confirm gemcitabine's efficacy and tolerability in treating various solid tumors.

Related Experiment Videos